Cubist submits regulatory filing for Ceftolozane

Cubist Pharmaceuticals (CBST -0.3%) submits its NDA for the antibiotic ceftolozane/tazobactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.

Last year the FDA granted the drug Fast Track status.

The company plans to file a Marketing Authorization Application with the European Medicines Agency in the second half of this year.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs